biOasis Technologies Ord Shs V.BTI.H

Gregory Bell, MD, Chief Medical Officer at Attralus

[Comonreally42]

"Encouraging preclinical data for AT-04 indicates that it potently binds to all types of amyloid, including synthetic fibrils composed of Aβ, tau, and α-synuclein, pathologic aggregates common to neurodegenerative disorders such as Alzheimer's," said Gregory Bell, MD, Chief Medical Officer at Attralus. "The addition of the TXP1 brain shuttle has the potential to significantly improve CNS penetration and efficacy. While most therapies in development target individual pathologies, such as Aβ, tau or α-synuclein, AT-04 can target all amyloid pathologies in each patient and has the potential to transform the lives of patients living with neurodegenerative disorders."

[JDavenport]

Let me explain something about the transferrin receptor (TfR), or any receptor, for that matter. Receptor-mediated transcytosis, as we use the term, requires something like xB3 to be attached to a therapeutic payload. xB3 is the "hook" that attaches to the receptor with the result that the xB3-Drug combination is pulled into the BBB cell and out its other side. It's the same